Importantly, SNHG7 is demonstrated as a potential therapeutical target as it is identified in several studies to lead to enhanced chemoresistance to several anticancer agents such as Cisplatin, Trastuzumab, and Folfirinox in the cancer cells (Chen et al., 2019d; Li et al., 2020a; Zhang et al., 2020b; Dai et al., 2020; Cheng et al., 2021; Pei et al., 2021). This evidence concerns the gene SNHG7 and cancer.